Hematologic Malignancies
Conference Coverage
Researchers consider R/R ALL drugs in the first-line setting
CHICAGO –
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
Conference Coverage
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
Conference Coverage
Implementation of a Hematology VA-ECHO Program
Conference Coverage
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid
News
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
News
FDA fast-tracks CX-01 for newly diagnosed AML
News
Fracture risk linked to mortality in women with myeloma
Researchers identified osteoporosis as an important prognostic factor in postmenopausal women.
News
Could An Antibiotic Be the Next Great Oncologic Drug?
A drug typically used to treat acne shows promise for treating different types of leukemia.